Government of India announces National Pharma Policy draft
With the aim to boost domestic manufacturing of drugs, levy cap on trade margin, crackdown on unfair marketing practices and limit
'loan licensing' by pharma companies, the government of India has conscripted National Pharma Policy draft.
The new draft policy also focuses on creating a national list of essential medicines with the target of keeping the reachable and reasonable. This step could be marked as the beginning of a new era in Indian pharmaceutical sector. The policy also talks about setting up of a National Pharmaceuticals Pricing Authority (NPPA).
The draft also aims to create an environment suitable for research and development.
The centre also plans to prescribe rules for branding drugs. Companies will be allowed to put brand names only on fixed-dose combinations. For all other drugs, they will be asked to print only the generic names.
The Authority is set to lose its autonomy with increase in interference from the government. While the policy says, “The regulator and the government would be two distinct agencies. The government shall not be the regulator and the regulator shall not be the government,” yet a government-appointed advisory body, with representation from the government, industry, as well as civil society, is being proposed.